Short answer
RHYTHM PHARMACEUTICALS, INC. (RYTM) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.3 (Exhibit EX-99.3), Item EX-99.2 (Exhibit EX-99.2). Q2 2026 financial results announced for quarter ended June 30, 2026.
RHYTHM PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Investor-relevant operating metrics and financial details contained in Exhibit 99.1 press release
- Results announcement provides the latest update on Rhythm Pharmaceuticals’ financial performance and condition
Item 7.01 · Regulation FD Disclosure
- Preliminary Phase 2 RM-718 data announced for acquired hypothalamic obesity
- Presentation available through Rhythm Pharmaceuticals’ Events and Presentations webpage
- Investors should assess efficacy and safety data under Item 8.01 for clinical-development implications
Item 8.01 · Other Events
- Preliminary Phase 2 data: RM-718 reduced mean BMI 11.6% at 16 weeks in acquired hypothalamic obesity patients
- Efficacy comparable to bivamelagon and setmelanotide benchmarks, each showing 10.1% mean BMI reduction
- Safety generally manageable, with injection-site reactions, nausea, and vomiting most common
- Two mild injection-site hyperpigmentation cases; no generalized hyperpigmentation observed
- Two patients discontinued for adverse events, while eight remained on active treatment as of July 16, 2026
Item EX-99.1 · Exhibit EX-99.1
- Q2 IMCIVREE revenue $71.3M, up 19% sequentially, signaling accelerating commercial adoption
- U.S. revenue $51.0M, up 38% sequentially, with 400+ acquired-HO start forms from approximately 300 prescribers
- RM-718 delivered 11.6% mean BMI reduction after 16 weeks in acquired-HO patients, supporting pipeline differentiation
- Cash, equivalents and short-term investments $330.9M, down from $388.9M at December 31, 2025
- Q2 net loss $50.4M, or $0.73 per share, while 2026 non-GAAP operating-expense guidance remains $363M to $397M
Item EX-99.2 · Exhibit EX-99.2
- RM-718 produced an encouraging -11.6% mean BMI reduction at Week 16, based on 7 patients with acquired hypothalamic obesity
- Efficacy broadly matched bivamelagon and setmelanotide comparators, each showing a -10.1% BMI reduction
- Limited hyperpigmentation: 2 mild cases, both confined to injection sites, supporting RM-718’s MC1R-sparing design
- Eight patients remained on treatment as of July 16, 2026, while 2 discontinued for adverse events
- Small, open-label dataset remains an early signal, with nausea, vomiting, and injection-site reactions reported as common adverse events
Item EX-99.3 · Exhibit EX-99.3
- Q2 2026 product revenue $71.3M, up from $48.5M, with 19% sequential growth and 72% from the U.S.
- IMCIVREE launch exceeded 400 patient start forms and reached approximately 300 prescribers by June 30, 2026
- RM-718 reduced mean BMI 11.6% at Week 16 in seven acquired hypothalamic obesity patients, but two discontinued for adverse events
- RM-718 adverse events included injection-site reactions in 81.8% and nausea in 54.5% of 11 patients
- Cash, equivalents and short-term investments $330.9M, supporting planned operations for at least 24 months; 2026 non-GAAP OpEx guidance $363M-$397M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RHYTHM PHARMACEUTICALS, INC. 8-K filings
Get the next RYTM 8-K as it lands
Follow RYTM for push alerts, or ask the research agent what this filing means.